FindTrial
Sign In

The Median Effective Volume and Concentration of Ropivacaine in Shoulder Joint Regional Analgesia

The Median Effective Volume and Concentration of Ropivacaine in Shoulder Joint Regional Analgesia

Status
Active, not recruiting
Phases
Phase 4
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2300070129
Enrollment
Unknown
Registered
2023-04-03
Start date
2023-05-01
Completion date
Unknown
Last updated
2023-05-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Postoperative shoulder pain

Interventions

Group of different volume:different volume of 0.375% ropivacaine
Group of different concentration:different concentration of 10ml ropivacaine

Sponsors

Nanjing First Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 70 Years

Inclusion criteria

Inclusion criteria: 1. Selected for arthroscopic shoulder surgery 2. Age between 18-70y 3. ASA between I-II 4. BMI between 18-30 kg/m2

Exclusion criteria

Exclusion criteria: 1. impaired coagulation function 2. uncontrolled hypertension 3. ischemic heart disease 4. cerebral ischemia/ hemorrhage 5. liver or kidney dysfunction

Design outcomes

Primary

MeasureTime frame
50% minimum effective volume;50% Minium Effective Concentration;—

Secondary

MeasureTime frame
Diaphragmatic Excursion;NRS score;—

Countries

China

Contacts

Public ContactYong Zhang

Nanjing First Hospital

zhangyongjxz@163.com+86 13770557940

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 8, 2026